$ILMN (Illumina Inc.)

$ILMN {{ '2016-07-26T23:07:49+0000' | timeago}} • Webcast

Isaac Ro of Goldman Sachs asks about GRAIL, the new company formed by $ILMN in Jan 2016. CEO Francis deSouza said that the GRAIL team is progressing and it is on track to develop the assay by the end of this year. GRAIL team is also working hard on designing the clinical trial. He added that there are no new updates at this point of time.

$ILMN {{ '2017-05-22T15:06:11+0000' | timeago}} • Announcement

$ILMN appointed Mark Van Oene as Chief Commercial Officer. Van Oene was previously $ILMN's SVP of the Americas region and subsequently named interim Chief Commercial Officer in late 2016. As Chief Commercial Officer, Van Oene will be responsible for world-wide sales, services and marketing at $ILMN. He will report to CEO Francis deSouza.

$ILMN {{ '2017-04-25T22:27:16+0000' | timeago}} • Webcast

$ILMN expects gross margin to be slightly lower in 2Q17 compared to 1Q17. The operating expense growth also is expected to the drive EPS. The company said that it is seeing new customers emerging in China and it remains bullish on the Chinese market opportunities.

$ILMN {{ '2017-04-25T20:37:01+0000' | timeago}} • Announcement

For 2Q17, $ILMN  expects revenue growth of approx. 7% versus a year ago. GAAP earnings per diluted share attributable to company stockholders is expected to be $0.56-0.61 and non-GAAP earnings per diluted share attributable to company stockholders is expected in the range of $0.65-0.70 for 2Q17.

$ILMN {{ '2017-04-25T20:36:13+0000' | timeago}} • Announcement

For FY17, $ILMN expects revenue growth in the range of 10-12%. Additionally, GAAP diluted EPS attributable to company stockholders is expected to be $5.26-5.36 and non-GAAP EPS attributable to company stockholders is expected to be $3.60-3.70 for FY17.

$ILMN {{ '2017-04-25T20:30:02+0000' | timeago}} • Announcement

Life science research company $ILMN's earnings for 1Q17 quadrupled, helped by a pre-tax gain of $453MM resulting from the GRAIL repurchase of shares from $ILMN. Net income jumped 314% to $373MM or $2.52 per share from $90MM or $0.60 per share a year ago. Revenue increased 4.54% to $598MM.

$ILMN {{ '2017-01-31T23:23:11+0000' | timeago}} • Webcast

$ILMN said that Asia Pacific had a significant growth in 4Q16 as revenue increased 29% YoverY, propelled by China which grew approx. 50%. Europe grew 11%, driven in part by year-end spending. Americas revenue declined 4% due to lower high throughput sequencing instrument shipments.

$ILMN {{ '2017-01-31T23:18:17+0000' | timeago}} • Webcast

$ILMN ended 2016 with approx. 35 HiSeq X customers and 37 HiSeq X instruments and backlogs, which are candidates for conversation to NovaSeq.

$ILMN {{ '2017-01-31T21:59:15+0000' | timeago}} • Announcement

For 1Q17, $ILMN expects revenue to be $580-595MM, GAAP diluted EPS attributable to company stockholders to be $0.51-0.56 and non-GAAP diluted EPS attributable to company stockholders to be $0.60-0.65.

$ILMN {{ '2017-01-31T21:58:45+0000' | timeago}} • Announcement

For FY17, $ILMN projects revenue to grow 10-12%, GAAP diluted EPS attributable to company stockholders to be $3.25-3.35 and non-GAAP diluted EPS attributable to company stockholders to be $3.60-3.70.

$ILMN {{ '2017-01-31T21:54:49+0000' | timeago}} • Announcement

$ILMN reported a rise in 4Q16 profit, helped by higher revenues. Net income rose 18.5% YoY to $123.8MM or $0.84 per diluted share. Revenue increased 5% to $619MM. Non-GAAP EPS was $0.85 compared to $0.81 in the prior year quarter.

$ILMN {{ '2017-01-27T16:35:34+0000' | timeago}} • Announcement

$ILMN appointed Caroline Dorsa to its BoD. Given her financial expertise, Dorsa will also participate on the Audit Committee of the Board. Most recently, as EVP and CFO at Public Service Enterprise Group, Dorsa led the finance, business development, and investor relations teams.

$ILMN {{ '2017-01-12T13:31:30+0000' | timeago}} • Announcement

$ILMN and NRGene announced a collaboration to develop new molecular breeding tools for cattle. As a first step, the companies also announced the completion of a high quality genome assembly of the Nellore cattle in conjunction with researchers at the Universidade Estadual Paulista in Brazil.

$IBM {{ '2017-01-09T14:58:32+0000' | timeago}} • Announcement

$IBM Watson Health and $ILMN announced a groundbreaking partnership to expand access to genome data interpretation by integrating Watson for Genomics into $ILMN's BaseSpace Sequence Hub and tumor sequencing process. The collaboration is designed to help standardize and simplify genomic data interpretation.

$ILMN {{ '2017-01-03T17:50:30+0000' | timeago}} • Announcement

$ILMN announced appointment of Garret Hampton, as EVP of Clinical Genomics,  starting Jan. 9, 2017. Garret will be responsible for leading the clinical genomics group, including the reproductive and genetic health and oncology businesses, regulatory, clinical and medical affairs and the Chief Medical Officer's organization.

$ILMN {{ '2016-12-20T15:37:16+0000' | timeago}} • Announcement

$ILMN announced the appointment of Jonathan Seaton as SVP for Corporate & Business Development. He will join the company on January 3, 2017. Mr. Seaton comes to $ILMN from Becton, Dickinson and Company where he was Vice President and Head of Strategy and Business Development for the Life Sciences segment.

$ILMN {{ '2016-12-07T13:36:43+0000' | timeago}} • Webcast

$ILMN said it extended its management team by appointing Sam Samad as SVP and CFO, who will join the company on Jan. 6, 2017.

$ILMN {{ '2016-11-01T23:05:38+0000' | timeago}} • Webcast

$ILMN stated that China is the company's number 2 country market. In China, $ILMN moved faster than it expected.

$ILMN {{ '2016-11-01T22:08:30+0000' | timeago}} • Webcast

$ILMN reported that Chief Commercial Officer Christian Henry will be leaving the company at the end of January. Mark Van Oene, GM of Americas business has been named as Interim CCO while $ILMN searches for a new CCO.

$ILMN {{ '2016-11-01T22:00:46+0000' | timeago}} • Webcast

In 3Q16, $ILMN submitted its companion diagnostic test for Vectibix, a drug used to treat a type of cancer, to FDA for the pre-market approval. Vectibix was developed by the company partnering with $AMGN.

$ILMN {{ '2016-11-01T20:33:06+0000' | timeago}} • Announcement

$ILMN continues to project 4Q16 revenue to be flat to slightly up compared to 3Q16. For FY16, the company lowered its non-GAAP EPS guidance to range of $3.27-3.32 from previous forecast range of $3.48-3.58. $ILMN now expects FY16 GAAP EPS in the range of $2.92-2.97.

Recent Transcripts

HON (Honeywell International Inc.)
Friday, July 21 2017 - 1:30pm
DHR (Danaher Corp.)
Thursday, July 20 2017 - 12:00pm
AA (Alcoa Inc.)
Wednesday, July 19 2017 - 9:00pm
A (Agilent Technologies Inc.)
Monday, May 22 2017 - 8:30pm
FLDM (Fluidigm Corporation)
Thursday, May 4 2017 - 9:00pm
PKI (PerkinElmer Inc.)
Thursday, May 4 2017 - 9:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 9:00pm
CBMX (CombiMatrix Corporation)
Thursday, May 4 2017 - 8:30pm
PSDV (pSivida Corp.)
Thursday, May 4 2017 - 8:30pm
MTD (Mettler-Toledo International Inc.)
Thursday, May 4 2017 - 12:00pm
QGEN (Qiagen NV)
Wednesday, May 3 2017 - 1:00pm
GNMK (GenMark Diagnostics, Inc.)
Tuesday, May 2 2017 - 8:30pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
SNE (Sony Corporation)
Friday, April 28 2017 - 8:15am
GOOGL (Alphabet Inc.)
Thursday, April 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
F (Ford Motor Co.)
Thursday, April 27 2017 - 1:00pm
AMGN (Amgen Inc)
Wednesday, April 26 2017 - 9:00pm
PACB (Pacific Biosciences of California, Inc.)
Wednesday, April 26 2017 - 8:30pm
IART (Integra LifeSciences Holdings Corporation)
Wednesday, April 26 2017 - 12:30pm

AlphaGraphics you may like